Stock Activity: Galena Biopharma Inc (NASDAQ:GALE), Oxford Industries Inc. (NYSE:OXM), Miller Industries Inc. (NYSE:MLR), Agios Pharmaceuticals (NASDAQ:AGIO), General Motors Company (NYSE:GM)


Galena Biopharma Inc (NASDAQ:GALE) shares remains unchanged in last trading session and ended the day at $1.49. GALE Gross Margin is 85.30% and its has a return on assets of -43.60%. Galena Biopharma Inc (NASDAQ:GALE) quarterly performance is -5.10%.

Galena Biopharma, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapeutics. Its development portfolio ranges from mid- to late-stage clinical assets, including immunotherapy program led by its lead product NeuVax (nelipepimut-S), which is in Phase III clinical trial and is a targeted cancer immunotherapy. GALE-301 is an immunogenic peptide and can stimulate cytotoxic T lymphocytes to recognize and destroy Folate Binding Protein-expressing cancer cells.

Galena Biopharma, Inc. (NASDAQ:GALE), announced that the Independent Data Monitoring Committee (IDMC) has recommended to the Company that it can reduce the cardiac toxicity monitoring for patients in its NeuVax(TM) (nelipepimut-S) Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) clinical trial.

Oxford Industries Inc. (NYSE:OXM) ended the last trading day at $82.49. Company weekly volatility is calculated as 4.17% and price to cash ratio as 153.67. Oxford Industries Inc. (NYSE:OXM) showed a weekly performance of -3.16%.

Oxford Industries, Inc. is a global apparel company. The Company designs, sources, markets and distributes products bearing the trademarks of its owned lifestyle brands, as well as certain licensed and private label apparel products.

Oxford Industries, Inc. (NYSE:OXM) will report its fiscal second quarter ended August 1, 2015 financial results on Wednesday, September 2, 2015 after the market close. The Company will also hold a conference call with senior management to discuss the financial results in detail at 4:30 p.m. ET.

On 27 August, Miller Industries Inc. (NYSE:MLR) shares advanced 1.43% and was closed at $20.52. MLR EPS growth in last 5 year was 20.80%. Miller Industries Inc. (NYSE:MLR) year to date (YTD) performance is 0.21%.

Miller Industries, Inc. is a manufacturer of towing and recovery equipment. The Company manufactures the bodies of wreckers and car carriers, which are installed on truck chassis manufactured by third parties.

Miller Industries Inc. (NYSE:MLR) announced that its Board of Directors has declared a quarterly cash dividend of $0.16 per share, payable September 21, 2015, to shareholders of record at the close of business on September 14, 2015.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares advanced 2.94% in last trading session and ended the day at $90.02. AGIO has a return on assets of -14.00%. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) quarterly performance is -26.23%.

Agios Pharmaceuticals, Inc. (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform.

General Motors Company (NYSE:GM) caters to the Consumer Goods space. It has a net profit margin of 3.00% and weekly performance is -7.33%. On the last day of trading company shares ended up $28.58. General Motors Company (NYSE:GM) distance from 50-day simple moving average (SMA50) is -10.55%.

General Motors Company (General Motors) designs, builds and sells cars, trucks and automobile parts across the world. The Company also provides automotive financing services through General Motors Financial Company, Inc. (GM Financial).

General Motors’ Company (General Motors) Flint Engine Operations recently built its millionth 1.4-liter engine and now is in its last week of making the motor. Engine No. 1 million was built about two weeks ago, according to GM spokesman Tom Wickham.


Leave a Reply

Your email address will not be published. Required fields are marked *